A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
about
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradationMechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pHThe PCSK9 decadePCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primatesProprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesTrafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainA PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivoIdentification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein ReceptorPhysiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Detection of fused genes in eukaryotic genomes using gene deFuser: analysis of the Tetrahymena thermophila genome.High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterolNovel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.A two-step binding model of PCSK9 interaction with the low density lipoprotein receptorEffects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia.An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genesImproved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia.PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.Lupin Peptides Modulate the Protein-Protein Interaction of PCSK9 with the Low Density Lipoprotein Receptor in HepG2 Cells.PCSK9 targets important for lipid metabolismStrategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.PCSK9: an emerging target for treatment of hypercholesterolemia.The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?Update of Clinical Trials of Anti-PCSK9 Antibodies.Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Genome Editing for the Study of Cardiovascular Diseases.Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2).Isolation and characterization of the circulating truncated form of PCSK9The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation
P2860
Q24294486-45F29A94-5E71-45BA-BA78-D6ED6D47AFD3Q24297165-A8311FC7-95F4-4B24-9D96-B812688ABFB7Q24615397-151EBD29-F4F8-4B9C-983D-BF31B0C6969AQ24633470-29D11504-45E4-4053-A0B1-8888E0A99F99Q27009477-6AF46B03-74C5-469D-AB17-3B513D016617Q27339783-90D8EC06-C8B3-4882-8A3E-AB87AAF695AAQ27665195-93D146CE-9E19-4245-A370-71835115E6B8Q27680601-2D60764A-295F-4B5B-9FCA-8F584ED97971Q33599961-0722BFFD-FC92-4E7A-9932-50219EFB5A09Q33957270-265A4013-AF03-49B6-9C82-41880C87C5D1Q34053143-D3EF1063-5645-40F8-8E0A-90650F33F8DFQ34227474-D44CB2F1-B430-4D26-9A3C-A76FA217D6C0Q34568486-E9995CAD-4B08-4E12-A7D3-A8490F02F43BQ34662589-0EF611D8-6AAC-439B-825F-9346CD76E1CEQ35612555-5344615D-5C09-4826-B52A-48E9A25A6A4AQ35625968-35493D2F-0B21-4F92-9686-9FECCABC0B0EQ35767551-B1BA02EC-8EC7-4773-8473-37662BC0D29AQ35771131-56210624-EF5F-4D69-9F3E-BA102ECB3B35Q35879455-2E3FBDD1-4258-404E-B1DE-0D9723336330Q35897064-87B00121-2441-4F0A-86D9-C4D2500F9A04Q36196833-48DA7321-AD84-4110-B651-48D5CADCF365Q36481769-2A4A5F03-60CC-43BB-8073-0690F2328E82Q37101312-0A8F4E7E-E221-40E9-A138-E123AB991E8CQ37703261-B7B81B7C-61A2-4EC1-90B0-0B84B2A95B49Q37789741-2A6494F2-2A13-46B4-AE31-3C0DC5C7BA43Q37825903-CFB4FDB9-628F-40D1-B4AD-FBF92B2F4759Q37880856-F15496BE-02A3-41CE-8ED7-29716BDE3835Q38109960-E77B4571-7A12-4841-BCA5-465924426ECEQ38151675-4CCF276F-978F-48A2-A943-1530DE4B8BCFQ38221015-5876B846-F368-4BE8-AF95-BB93F3815FDAQ38444379-2EA44AE4-E12B-447A-8F11-FA8DAF08A213Q38653210-71C5E9D2-23AD-4B92-B7C5-8CB7C6650B85Q38855416-9903FEAE-1A18-4635-B690-20568C117CA3Q39030028-BC7F00FA-3548-467B-8115-D005435ACAA1Q39144904-52F316DD-1BCB-4321-86E4-011582A9A2E8Q39795723-0436B4F3-9FC8-4B01-A1C9-5DAAB36D5C9DQ41518234-CB8D33FB-2627-4845-B1AA-4AC804A099C6Q41851719-866421CD-F629-4879-B76C-3DFAC8CA1C6BQ41917702-A3FCA9D8-FA02-418B-90C2-14725ADD2F9AQ42136107-497D5B59-AA3C-42AB-AAA6-1C401DE292CB
P2860
A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A proprotein convertase subtil ...... ow density lipoprotein uptake.
@ast
A proprotein convertase subtil ...... ow density lipoprotein uptake.
@en
A proprotein convertase subtilisin-like/kexin type 9
@nl
type
label
A proprotein convertase subtil ...... ow density lipoprotein uptake.
@ast
A proprotein convertase subtil ...... ow density lipoprotein uptake.
@en
A proprotein convertase subtilisin-like/kexin type 9
@nl
prefLabel
A proprotein convertase subtil ...... ow density lipoprotein uptake.
@ast
A proprotein convertase subtil ...... ow density lipoprotein uptake.
@en
A proprotein convertase subtilisin-like/kexin type 9
@nl
P2093
P2860
P356
P1476
A proprotein convertase subtil ...... ow density lipoprotein uptake.
@en
P2093
Alessia Noto
Andrea Carfí
Anka Ehrhardt
Ayesha Sitlani
Brian Hubbard
Cinzia Volpari
Dale Lewis
Dana D Wood
Douglas Wisniewski
Holly A Hammond
P2860
P304
12882-12891
P356
10.1074/JBC.M110.113035
P407
P577
2010-02-19T00:00:00Z